Wikipedia -WSS

Wikipedia

author：explore 2025-08-12 05:30:44 - browse：24623

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Medicare has officially expanded its coverage policy for brain scans that detect a brain plaque associated with Alzheimer’s disease, the agency announced on Friday.

Amyloid PET scans are important tools to help determine whether patients with mild cognitive impairment are good candidates for new Alzheimer’s drugs, including Eisai and Biogen’s drug Leqembi, which means there will likely be an increase in demand for the scans as uptake increases.

Previously, Medicare limited coverage for the drug to patients enrolled in clinical studies, and only covered one scan in a patient’s lifetime. The new coverage policy removes those restrictions and delegates decisions about how many scans to cover to regional Medicare administrators.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Naloxone nonprofit donates 200,000 doses after FDA approval

focus

entertainment

WSS

Wegovy’s successful heart trial raises vital question about weight loss

Roivant's CEO is a star, but biotech's black hole persists

Wegovy trial has doctors encouraged over new possibilities

How AI can help patients find reliable information about doctors

American woman, child freed after being kidnapped in Haiti last month

A biotech analyst on neuroscience, placebo effect, not over

entertainment

Wikipedia

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

Friends ask where James Watson's attitudes about race came from

Medicare details structure of new drug price negotiation program

Why a market frenzy over new weight loss drugs defies logic

State Dept. review finds Biden bears some blame for Afghanistan failures

Wegovy’s successful heart trial raises vital question about weight loss

Jerome Adams on the need for new antivirals for Covid

Wegovy’s successful heart trial raises vital question about weight loss

Hollywood unions extend contract negotiations for actors

For Cytokinetics, FDA rejection of heart drug would help, not hinder

leisure time

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

STAT Summit: The economic case for universal basic health care

FDA panel issues narrow recommendation for Covid vaccine booster doses

Roche drug slashes death risk in early

Police still searching for prisoner who escaped from NYC hospital

Wegovy’s successful heart trial raises vital question about weight loss

focus

entertainment

leisure time

hotspot